Kidney Disease & Nephrology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU

This Phase 3 trial studied the drug eculizumab in children suffering from Shiga-toxin related hemolytic uremic syndrome, a severe kidney condition with limited treatment options. Conducted in France with 100 pediatric patients, the study explored whether early use of this antibody could improve recovery and long-term kidney health. The results may offer new hope for families facing this serious childhood illness by potentially establishing an effective therapy where none currently exists.

Immunogenicity of HPV Vaccine in Transplant Recipients

This Phase 4 trial is evaluating how well patients who have received a kidney transplant respond to the HPV vaccine. Because transplant recipients take medications that weaken their immune system, it is important to understand if vaccines provide adequate protection. This study, active in the United States with about 30 participants, could help inform vaccine recommendations and improve prevention of HPV-related diseases in this vulnerable group.

Chronic Kidney Disease-Education (CKD-EDU)

This study is testing two educational programs aimed at helping older adults with advanced chronic kidney disease better understand their treatment options. By improving patient knowledge and decision-making, the programs hope to reduce hospital visits and improve overall care. Recruiting in the United States, the study will assess the impact of education after 12 weeks, possibly offering new tools to support patients managing kidney disease.

Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

This trial is investigating a structured treatment approach for people with diabetic kidney disease, focusing on early, goal-directed therapy to reduce risks to both the kidneys and heart. Conducted in Ontario with about 100 participants, the study seeks to provide a more proactive way to manage this common complication of diabetes. If successful, it could improve long-term health outcomes by better controlling disease progression and related cardiovascular issues.

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

This study is testing a smartphone app designed to help adults with chronic kidney disease follow the latest KDIGO guidelines. The app offers personalized advice and reminders to support better management of kidney health, including controlling protein levels and blood pressure. Recruiting in Ireland, the trial includes young adults transitioning to adult kidney care and aims to slow disease progression through improved guideline adherence.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.